Results 51 to 60 of about 924 (199)

OXA-carbapenemases and mutations within PBPs in ST2 carbapenem-resistant A. baumannii: Evaluating the efficacy of cefiderocol and ampicillin-sulbactam combination therapy [PDF]

Objectives: Carbapenem-resistant Acinetobacter baumannii (A. baumannii; CRAB) isolates represent a serious public health concern. Recently, a novel molecule, the cefiderocol (FDC), has emerged as a promising therapeutic option for CRAB infections. In the
Carannante N., Giuliano S., Mariano B., Martini L., Perilli M., Piccirilli A., Tascini C.   +6 more
core   +1 more source

In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii

Journal of Antimicrobial Chemotherapy, 2020
AbstractObjectivesTo evaluate the activity of the novel broad-spectrum serine β-lactamase inhibitor durlobactam (ETX2514) combined with sulbactam against global isolates of carbapenem-resistant Acinetobacter baumannii with defined carbapenem resistance mechanisms compared with reference antimicrobials with known activity against Acinetobacter spp ...
Harald Seifert, Carina Müller, Danuta Stefanik, Paul G Higgins, Alita Miller, Michael Kresken   +5 more
openaire   +2 more sources

In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China

Journal of Antimicrobial Chemotherapy, 2020
AbstractBackgroundDurlobactam is a broad-spectrum inhibitor of class A, C and D β-lactamases. Sulbactam is a generic β-lactam most commonly used as a β-lactamase inhibitor in combination with ampicillin; however, it has a unique property in that it has selective intrinsic activity against Acinetobacter baumannii.
Harald Reinhart, Patricia A Bradford, Meredith Hackel, Jun Deng, Ge Zhang, Jingjia Zhang, Ying Zhu, Peiyao Jia, Yingchun Xu, Qiwen Yang   +9 more
openaire   +2 more sources

Microbial Etiology and Antimicrobial Resistance in Pneumonia Among Hospitalized Patients in Kazakhstan: A Systematic Review and Single‐Arm Meta‐Analysis of Prevalence Data

Health Science Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Background and Aims Pneumonia is an inflammatory condition of the lower respiratory tract, commonly caused by infection and associated with substantial morbidity and healthcare utilization. The burden of pneumonia on healthcare is exacerbated by limited data on pathogenic causes and associated antimicrobial resistance (AMR). Here, we conducted
Radmir Sarsenov, Maxim Solomadin, Alyona Lavrinenko, Vyacheslav Beloussov, Vitaliy Strochkov, Shynggys Orkara, Nurlan Sandybayev, Sergey Yegorov   +7 more
wiley   +1 more source

Potential role of avibactam in restoring susceptibility in Escherichia coli with two copies of blaKPC-3 and PBP3 mutations [PDF]

Unlabelled: The emergence of carbapenemase-producing Enterobacterales represents a significant clinical challenge. Resistance mechanisms involve carbapenemase production, porin and efflux pump alterations, penicillin-binding protein (PBP) modifications ...
Angelini, Jacopo, Arcamone, Celeste, Bernaschi, Paola, Bulfoni, Michela, Curcio, Francesco, Di Gennaro, Ciro, Ferin, Sara, Fox, Valeria, Giuliano, Simone, Gualandi, Nicolò, Krpan, Beatrice, Manzi, Rosa, Martini, Luca, Moreal, Chiara, Perno, Carlo Federico, Pipan, Corrado, Stanziola, Maria Cristina, Tascini, Carlo, Turco, Sara   +18 more
core   +1 more source

In vitro and in vivo evaluation of two combined β-lactamase inhibitors against carbapenem-resistant Acinetobacter baumannii [PDF]

, 2023
The objective of this study was to evaluate the in vitro and in vivo efficacy of clavulanic acid (C/A) in combination with tazobactam against clinical strains of carbapenem-resistant Acinetobacter baumannii. The MIC of 24 clinical strains of A. baumannii
Vila Domínguez, Andrea, Molina Panadero, Irene, Smani, Younes   +2 more
core   +1 more source

A Review of β‐Lactamase Inhibitors in Clinical Use and Development: Mechanisms, Spectrum, and Therapeutic Applications

International Journal of Microbiology, Volume 2026, Issue 1, 2026.
β‐Lactam antibiotics have long served as a cornerstone for treating bacterial infections. However, their widespread and often indiscriminate use has fueled the emergence of multidrug‐resistant Gram‐negative pathogens, primarily through the production and dissemination of β‐lactamase enzymes.
Mohammad Javad Roustaye Gourabi, Anita Nikoo, Bita Khanbabaei, Masoud Kargar, Amirhossein Fayyazi, Seyyed Mohammad Javad Mousavi, Amirhossein Aghdaee, Ali Hashemi, Javad Yasbolaghi Sharahi, Swaran J. S. Flora   +9 more
wiley   +1 more source

Abstract Supplement

Pulmonary Medicine, Volume 2026, Issue 1, 2026.
 
Marzia Folegani, Semonti Nandi
wiley   +1 more source

Antibiotic Resistance: A Genetic and Physiological Perspective

MedComm, Volume 6, Issue 11, November 2025.
The development of resistance to antimicrobials and their historical progression are depicted in this graphic. It draws attention to important biochemical, physiological, and genetic factors that contribute to AMR, such as the transmission of genes, the development of biofilms, and the inactivation of antibiotics.
Rania G. Elbaiomy, Ahmed H. El‐Sappah, Rong Guo, Xiaoling Luo, Shiyuan Deng, Meifang Du, Xiaohong Jian, Mohammed Bakeer, Zaixin Li, Zhi Zhang   +9 more
wiley   +1 more source

Combination Versus Monotherapy for Carbapenem-Resistant Acinetobacter Species Serious Infections: A Prospective IPTW Adjusted Cohort Study [PDF]

Introduction: International guidelines recommend definitive combination antibiotic therapy for the management of serious infections involving carbapenem-resistant Acinetobacter (CRAB) species.
Abraham, Ooriapadickal Cherian, Bhanuprasad, Kundakarla, Chacko, Binila, Gautam, Priyanka, George, Biju, George, Mithun Mohan, Hansdak, Samuel George, Iyadurai, Ramya, Karthik, Rajiv, Krishnan, Ramya, Kulkarni, Uday, Lal, Binesh, Manesh, Abi, Mathews, Vikram, Mo, Yin, Nagaraj, V., Nivetha, G., Palanikumar, Prasannakumar, Peter, John Victor, Rao, Shoma, Sathyendra, Sowmya, Subramani, K., Triveni, K. Rajitha, Zachariah, Anand   +23 more
core   +2 more sources